nach oben

Erschienen in:

01.05.2012 | Original Article

Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer

verfasst von: Angela S. Alberga, Roanne J. Segal, Robert D. Reid, Chris G. Scott, Ronald J. Sigal, Farah Khandwala, James Jaffey, George A. Wells, Glen P. Kenny

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to examine the effects of age (≤65 years or >65 years) and androgen-deprivation therapy (ADT, presence or absence) as factors that may predict changes in body composition and fitness following a 24-week exercise program in prostate cancer patients.

Methods

One hundred twenty-one men were randomly allocated to either: (1) aerobic exercise (AE), (2) resistance exercise (RE), or (3) usual care (UC). Body composition was assessed by DXA. Aerobic fitness was assessed through a maximal treadmill test. Muscular strength was assessed by leg extension and bench press using the eight-repetition maximum test. Responses were compared between younger (≤65 years) and older (>65 years) patients with or without ADT.

Results

There did not appear to be an interaction between age and ADT on body composition or fitness, nor were there any significant changes in body composition for participants ≤65 years. In participants aged >65 years, lean mass decreased in AE (p = 0.013) and UC (p = 0.006), but was preserved in RE. In participants receiving ADT, there was a decrease in lean mass in AE (p = 0.003) and UC (p < 0.001) but not in RE. The non-ADT group did not show any changes in body composition but did show improvements in muscular fitness following resistance training (p < 0.001).

Conclusion

Changes in body composition and physical fitness following a 24-week exercise program in men with prostate cancer are not influenced by age and/or ADT. Resistance training appears to attenuate the age-related decrease in lean mass and increase in body fat in older patients with prostate cancer and those receiving ADT.

Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA (2000) A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer 88(2):425–432PubMedCrossRef

Damber JE (2004) Decreasing mortality rates for prostate cancer: possible role of hormonal therapy? BJU Int 93(6):695–701PubMedCrossRef

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56(6):779–786CrossRef

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87(2):599–603PubMedCrossRef

Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL (2002) Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95(10):2136–2144PubMedCrossRef

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164PubMedCrossRef

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417PubMedCrossRef

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166(4):465–471PubMedCrossRef

Lee H, McGovern K, Finkelstein JS, Smith MR (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104(8):1633–1637PubMedCrossRef

10.

Stiegler P, Cunliffe A (2006) The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med 36(3):239–262PubMedCrossRef

11.

Roberts SB, Rosenberg I (2006) Nutrition and aging: changes in the regulation of energy metabolism with aging. Physiol Rev 86(2):651–667PubMedCrossRef

12.

Kenny GP, Yardley JE, Martineau L, Jay O (2008) Physical work capacity in older adults: implications for the aging worker. Am J Ind Med 51(8):610–625PubMedCrossRef

13.

Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–1426PubMedCrossRef

14.

Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D’Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27(3):344–351PubMedCrossRef

15.

Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan AJ, Monga TN, Zimmermann KP (2007) Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 88(11):1416–1422PubMedCrossRef

16.

Windsor PM, Nicol KF, Potter J (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101(3):550–557PubMedCrossRef

17.

Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347PubMedCrossRef

18.

Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D’Angelo ME, Wells GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653–1659PubMedCrossRef

19.

Hansen PA, Dechet CB, Porucznik CA, LaStayo PC (2009) Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. PM R 1(11):1019–1024PubMedCrossRef

20.

Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38(12):2045–2052PubMedCrossRef

21.

Landers J (1985) Maximums based on reps. Nat Strength Cond Assoc J 6:60–61

22.

Baechle T, Earle R (2000) Essentials of strength training and conditioning, 2nd edn. Human Kinetics, Champaign

23.

Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, Segal RJ (2008) Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer 112(8):1845–1853PubMedCrossRef

24.

Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA (2004) Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. J Clin Epidemiol 57(6):571–579PubMedCrossRef

25.

Galvao DA, Taaffe DR, Spry N, Newton RU (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 10(4):340–346PubMedCrossRef

26.

Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL (2007) Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 87(10):1325–1333PubMedCrossRef

27.

Boxer RS, Kenny AM, Dowsett R, Taxel P (2005) The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 8(3–4):207–212PubMedCrossRef

28.

Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR (2007) Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 29(1):118–127PubMed

29.

Dacal K, Sereika SM, Greenspan SL (2006) Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54(1):85–90PubMedCrossRef

30.

Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG (2008) Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 72(2):422–427PubMedCrossRef

31.

Bylow K, Mohile SG, Stadler WM, Dale W (2007) Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? A conceptual review. Cancer 110(12):2604–2613PubMedCrossRef

Titel: Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer
verfasst von: Angela S. Alberga
Roanne J. Segal
Robert D. Reid
Chris G. Scott
Ronald J. Sigal
Farah Khandwala
James Jaffey
George A. Wells
Glen P. Kenny
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 5/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1169-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer